share_log

創勝集團(06628.HK)治療胃癌藥物中位無進展生存期14.2個月

AASTOCKS ·  Sep 19, 2024 00:54

創勝集團(06628.HK)公布,Osemitamab (TST001)聯合納武利尤單抗和CAPOX作為晚期胃或胃食管結合部腺癌(TranStar102)一線治療的G隊列更新研究數據。該隊列的數據自ASCO 2024年會公布以來,持續顯示出令人鼓舞的療效。

研究結果顯示,在已知CLDN18.2和PD-L1表達水平的患者中,CLDN18.2高/中表達患者的中位無進展生存期(mPFS)為14.2個月,確認客觀緩解率為68%。其中絕大部分患者是PD-L1 CPS<5。

截至數據統計日期,由於事件數量有限,中位總生存期尚未達到,該隊列中總體人群(82名患者)的12個月生存率為73.8% (95% CI:62.0-82.4%)。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 389

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.